Business Wire

CA-UC-DAVIS-HEALTH

13.7.2020 13:02:05 CEST | Business Wire | Press release

Share
UC Davis Health Study Finds Special Filters in Glasses Help the Color Blind See Colors Better

A new UC Davis Eye Center study , in collaboration with France’s INSERM Stem Cell and Brain Research Institute , found that special patented glasses engineered with technically advanced spectral notch filters enhance color vision for those with the most common types of red-green color vision deficiency (“anomalous trichromacy”). Notably, the ability to identify and experience expanded color was also demonstrated when color blind test subjects were not wearing the glasses.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200713005065/en/

At least eight in 100 men (8%) and one in 200 women (0.5%) suffer from red-green color vision deficiency (CVD), totaling 13 million in the U.S. and 350 million worldwide. While those with normal color vision see in excess of one million hues and shades, the CVD see a vastly diminished range of colors. People with CVD experience colors as more muted and washed out, and some colors cause confusion or are more difficult to differentiate. With an undergraduate and graduate student body of nearly 40,000, UC Davis has an estimated 1,700 students with red-green CVD.

The study evaluated the impact of spectral notch filters on enhancing the chromatic responses of observers with red-green CVD over two weeks of usage. The filters (EnChroma glasses) are designed to increase the separation between color channels to help people with color blindness see colors more vibrantly, clearly and distinctly.

The research, published in Current Biology , had CVD participants wear the special filter glasses or placebo glasses. Over two weeks, they kept a diary and were re-tested on days 2, 4 and 11 but without wearing the glasses. The researchers found that wearing the filter glasses increased responses to chromatic contrast response in individuals with red-green color blindness. It is unclear how long the improvement lasts without wearing the filters, but the evidence shows that the effect persists for some time.

“Extended usage of these glasses boosts chromatic response in those with anomalous trichromacy (red-green color vision deficiency),” said John S. Werner , distinguished professor of ophthalmology and a leader in vision science at UC Davis Health. “We found that sustained use over two weeks not only led to increased chromatic contrast response, but, importantly, these improvements persisted when tested without the filters, thereby demonstrating an adaptive visual response.”

Werner noted that this effect cannot be achieved with broad-band filters sold as aids to the color blind. He and his research colleagues believe the study’s findings suggest that modifications of photoreceptor signals activate a plastic post-receptoral substrate in the brain that could potentially be exploited for visual rehabilitation.

“When I wear the glasses outside, all the colors are extremely vibrant and saturated, and I can look at trees and clearly tell that each tree has a slightly different shade of green compared to the rest," said Alex Zbylut, one of the color blind participants in the study who got the placebo glasses first and then tried the special filter version afterwards. "I had no idea how colorful the world is and feel these glasses can help color blind people better navigate color and appreciate the world."

Reactions from other participants about their experiences with the glasses can be found in the Supplement section of the Current Biology article.

Werner, lead author of the study, has published numerous scholarly works and was awarded the prestigious 2015 Verriest Medal from the International Colour Vision Society.

Co-authors on the study, Adaptive Changes in Color Vision from Long-Term Filter Usage in Anomalous but Not Normal Trichromacy , include Kenneth Knoblauch of the Université de Lyon and Inserm Stem Cell and Brain Research Institute in France, and Brennan Marsh-Armstrong, a medical student now at UC San Diego. The research was supported by the National Eye Institute and grants from LABEX CORTEX, Universite de Lyon, operated by the French National Research Agency.

Social Media:

https://www.facebook.com/UCDavisEyeCenter/

https://www.facebook.com/UCDavisHealth/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release

Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month

Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release

Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal

PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release

Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release

− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex

Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release

Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye